Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team

What are you looking for?

  • Conference Roundup
  • Contact Lenses
  • Diagnostics
  • Glaucoma
  • Myopia
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Retina
  • Spotlight Series
Navigating Presbyopia Conversations with Patients in Practice
Optometry 360
  • Home
  • Conferences
  • Videos
  • About Us
    • About Us – Mission
    • Media Partners
    • Advisory Board
    • Industry Council
    • Business Team
Home > Review outlines LipiFlow’s role in routine MGD management
  • Ocular Surface Disease

Review outlines LipiFlow’s role in routine MGD management

Kelsey Moroz

A new review in Ophthalmology and Therapy describes how the LipiFlow Thermal Pulsation System helped shift therapeutic meibomian gland expression from an underused procedure to a routine part of meibomian gland dysfunction (MGD) management.

The authors note that although manual gland expression was known to improve tear film stability, it was not widely used because it was uncomfortable for patients and difficult to perform consistently in clinic. LipiFlow was developed to address these challenges by combining controlled heat to the inner eyelids with pulsatile pressure to the outer lids to evacuate obstructed glands during a 12-minute in-office treatment.

According to the review, more than 55 studies involving over 2,100 patients have evaluated LipiFlow. These studies reported improvements in both signs and symptoms of MGD and dry eye disease following a single treatment, with benefits lasting up to 3 years in some cases.

The review also describes how standardized diagnostic tools, including the meibomian gland evaluator, have supported more consistent assessment and treatment of gland function in clinical practice.

Reference
Blackie CA, Murakami D, Donnenfeld E, et al. LipiFlow and the Transformation of Therapeutic Meibomian Gland Expression into Routine Clinical Practice. Ophthalmol Ther. 2026;doi: 10.1007/s40123-026-01309-0. Epub ahead of print. PMID: 41609975.

Share

Related Content

  • Conference Roundup

Affects dry eye can have on patients’ quality of life and more highlights from Academy 2026

  • Ocular Surface Disease

Apraclonidine 0.125% maintains ocular redness reduction over 8 weeks

  • Ocular Surface Disease

Greater screen use linked to dry eye symptoms in children

  • Trending Topics

GLP-1 receptor agonist use tied to higher NAION risk

  • Ocular Surface Disease

Smartphone reminders improve short-term artificial tear adherence in dry eye disease

  • Ocular Surface Disease

Childhood-onset allergic eye disease linked to greater ocular morbidity

Share

Advisory Board

Kaleb Abbott, OD, MS, FAAO

Clark Chang, OD

Jessica Haynes, OD, FAAO, FORS, Dipl ABO

Monica Kalia, OD

Cecelia Koetting, OD, FAAO, DipABO

Roya Attar, OD, MBA, DHA, FAAO

Hardeep Kataria, OD, FAAO

Marc R. Bloomenstein, OD, FAAO

Elise Kramer, OD

See All
Optometry 360

Optometry 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

© 2026 Optometry 360 is a trademark of International Healthcare Media, LLC. All rights Reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophthalmology360 Icon